Most previous studies were carried out on lung carcinoma cells or immortalized cell lines, or in animal models of growing lung cancers, and described PPARγ agonists as inhibitors of lung oxidative stress and cell-cycle progression [1,22]. The gene discussed is PPARG; the disease is lung carcinoma.